PPT-State of the Art Therapy for HCV

Author : liane-varnes | Published Date : 2015-10-23

Last Updated February 21 2014 Robert G Gish MD Senior Medical Director St Josephs Hospital and Medical Center Liver Program Phoenix Arizona Clinical Professor of

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "State of the Art Therapy for HCV" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

State of the Art Therapy for HCV: Transcript

Last Updated February 21 2014 Robert G Gish MD Senior Medical Director St Josephs Hospital and Medical Center Liver Program Phoenix Arizona Clinical Professor of Medicine University of Nevada Las Vegas. Todd S. Wills, MD. SPNS HCV Treatment Expansion Initiative. Evaluation and Technical Assistance Center. Infectious Disease Specialist. HCV Response Rates in HIV+ and HIV- Patients Treated With . PegIFN. Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors. Disclosures. Introduction. SILEN-C1 trial. Virologic response. a. Methods. Baseline characteristics. ASTRAL-1. Phase 3. . Treatment. . Naïve & Experienced. Feld JJ, . et al. . N . Engl. J Med. . 2015. ;373:2599-607.. Source: Feld . JJ. , et al. N . Engl. J Med. . 2015. ;373:2599-607.. Sofosbuvir-Velpatasvir. . current practice and future capacity.. Vendula. Belackova. 1. Allison Salmon. 1. Eberhard Schatz. 2. Marianne . Jauncey. 1. William Wood. 1. International Network of . Drug Consumption Rooms. 1. This program is s. upported. by educational grants from AbbVie; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and . ViiV. Healthcare. . About These Slides. Please feel free to use, update, and share some or all of these slides in your noncommercial presentations to colleagues or patients. Co-Infection – Florida, . 2014. . STD and Hepatitis Section in collaboration with HIV/AIDS Section – Surveillance Unit . Division of Disease Control and Health Protection. HIV Disease data from 1981 through December . Amber Wheeler, MD. WIHS Scientific Meeting. June 30, 2014. Objectives. To discuss:. Background . Aims. Preliminary “rough” data. Future Directions. HIV-infected . persons have increased. odds of . Objectives. Define elimination as it relates to infectious diseases. Understand the gaps in the current cascade of care for HCV. Identify interventions required to achieve HCV elimination in a defined population. 30. 40. 50. 60. 70. 80. 90. 1. 00. 0 . 1. 0. . 20. Days Since. . Infection. HIV RNA. . (plasma). HIV. . Antibody. HIV p24. . Ag. IgM. IgG. FIGURE . 1: LABORATORY . MARKERS . OF HIV. . INFECTION. Co-Infection – Florida, . 2013. . STD and Hepatitis Section in collaboration with HIV/AIDS Section – Surveillance Unit . Division of Disease Control and Health Protection. HIV Disease data from 1981 through December . La gamme de thé MORPHEE vise toute générations recherchant le sommeil paisible tant désiré et non procuré par tout types de médicaments. Essentiellement composé de feuille de morphine, ce thé vous assurera d’un rétablissement digne d’un voyage sur . Sam Lam, . PharmD. Annie Vong, . PharmD. 2/3/2017. Available HCV treatment DAAs. Epclusa. (. sofosbuvir. / . velpatasvir. ). Harvoni. (. sofosbuvir. / . ledipasvir. ). Zepatier. (. grazoprevir. / . Mark Sulkowski, . MD. Professor of Medicine. Medical Director, Viral Hepatitis Center . Johns Hopkins University. Baltimore Maryland USA. Liver disease is the second leading specific causes of death amongst HIV-positive individuals in the D:A:D study. & . Update on HCV . blood bank protocol. . Overview - . diagnostic tests. Serologic . assays: . specific antibody to hepatitis C virus (anti-HCV). Molecular . assays: HCV nucleic acid . (. nucleic.

Download Document

Here is the link to download the presentation.
"State of the Art Therapy for HCV"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.